Allogene Therapeutics Inc (NASDAQ:ALLO) currently has a daily average trading volume of 5.24M but it saw 4399145 shares traded in last market. With a market cap of 238.42M USD, the company’s current market price of $1.09 came rising about 14.40 while comparing to the previous closing price of $0.95. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.78 and as low as $0.86.
Taking a look at 20-day trading activity of Allogene Therapeutics Inc (ALLO) gives us an average price of $1.4076, while its current price level is -71.16% below from 52-week high level whereas it is 26.44% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.5435 while that of 200 days or SMA-200 reads an average of $2.1601. A closer look into the stock’s movement over the week reveals that its volatility is standing at 15.48% during that period while stretching the period over a month that decreases to 11.06%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 35.15 which implies that the stock is in neutral territory.
Citizens JMP upgraded its recommendation for the stock as a “Mkt Outperform” from “Mkt Perform” on March 14, 2025 while assigning a price target of $5. Oppenheimer issued its recommendations for the stock as it resumed the price target for the stock in the range of between $13 and $11.
Over the week, ALLO’s stock price is moving -7.63% down while it is -25.34% when we observe its performance for the past one month. Year-to-date it is -48.83% down and over the past year, the stock is showing a downside performance of -62.41%.
Currently, Allogene Therapeutics Inc’s total number of outstanding shares is 218.60M with 17.21% of that held by the insiders while 76.33% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -54.07% and return on equity (ROE) at -59.60%. Stock’s beta reads 0.27. Stock has a price to book (P/B) ratio of 0.62. Its return on asset (ROA) is -46.11% on average.
